Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 1431 • ACR Convergence 2022
Impact of Tofacitinib on Fracture Risk in Rheumatoid Arthritis
Karen E Hansen¹, Mahta Mortezavi², Edward Nagy³, Cunshan Wang⁴, Carol A Connell⁴, Zaher Radi⁵, Heather J Litman⁶, Giovanni Adami⁷ and Maurizio Rossini⁷, ¹Rheumatology Division, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Pfizer Inc, New York, NY, ³Pfizer Ltd, Tadworth, United Kingdom, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc., Cambridge, MA, ⁶CorEvitas, LLC, Waltham, MA, ⁷Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy
Background/Purpose: Preclinical data suggest that tofacitinib stimulates osteoblast function and would have a protective effect on bone health and fracture risk in RA.1 We report…
Abstract Number: 1887 • ACR Convergence 2022
Determining the Long-term Safety and Efficacy of JAK Inhibitors in the Treatment of Dermatomyositis: A Retrospective Cohort Study
Shivani Rangaswamy¹, Lisa Christopher-Stine², Jemima Albayda², Eleni Tiniakou², Christopher Mecoli³, Brittany Adler², Ellen Eline², William Kelly² and Julie Paik², ¹Johns Hopkins School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: JAK inhibitors have been reported to be a promising treatment for dermatomyositis, an idiopathic inflammatory myopathy. However, the FDA recently added a black box…
Abstract Number: 2138 • ACR Convergence 2022
Real-world Persistence and Treatment Patterns in Psoriatic Arthritis Patients Treated with Anti-IL17 Therapy
BEATRIZ E. JOVEN¹, Concepción Fito Manteca², Enrique Rubio³, Enrique Raya Álvarez⁴, Alba Pérez⁵, Raquel Hernández⁶, Sara Manrique Arija⁷, Mercedes Núñez⁸, Silvia Díaz⁸, Luis Trancho⁸, Sebastian Moyano⁸, Alessandra Lacetera⁹, Noelia Alfaro-Oliver⁹ and Rosario Garcia-Vicuña¹⁰, ¹Hospital Universitario 12 de Octubre, Madrid, Spain, ²Hospitalario de Navarra, Pamplona, Spain, ³Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁴Hospital Universitario San Cecilio, Granada, Spain, ⁵Hospital Puerta del Mar, Cádiz, Spain, ⁶Virgen de Valme University Hospital, Sevilla, Spain, ⁷Hospital Regional Universitario Málaga, Málaga, Spain, ⁸Lilly, Alcobendas, Spain, ⁹OXON Epidemiology, Madrid, Spain, ¹⁰Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain
Background/Purpose: Interleukin-17A inhibitors (anti-IL17) have provided an additional treatment option in the management of the psoriatic arthritis (PsA). This study aims to describe the patient…
Abstract Number: 0080 • ACR Convergence 2022
Utilization of Biologic and Targeted Disease Modifying Antirheumatic Therapy in Patients with Rheumatoid Arthritis and Breast Cancer
Juan Ruiz¹, Chi-Fang Wu², Hui Zhao², Sharon Giordano², Suja Rajan³ and Maria Suarez-Almazor⁴, ¹The University of Texas MD Anderson Cancer Center, Houston, TX, ²The University of Texas, MD Anderson Cancer Center, Houston, TX, ³University of Texas School of Public Health, Houston, TX, ⁴MD Anderson Cancer Center, Houston, TX
Background/Purpose: Biologic and targeted synthetic disease modifying antirheumatic drugs (bDMARD and tsDMARD) are immunosuppressant, and there have been concerns that they might impact tumor immunity…
Abstract Number: 0294 • ACR Convergence 2022
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic DMARDs: Results Through 5 Years from the SELECT-BEYOND Study
Roy Fleischmann¹, Sebastian Meerwein², Christina Charles-Schoeman³, BERNARD COMBE⁴, Stephen Hall⁵, Nasser Khan⁶, Kyle Carter⁷, Heidi Camp⁸ and Andrea Rubbert-Roth⁹, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²AbbVie Deutschland GmbH & Co KG, LUDWIGSHAFEN, Germany, ³Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA, ⁴Montpellier University, Montpellier, France, ⁵Emeritus Research and Monash University, Melbourne, Australia, ⁶AbbVie, Inc., Abbott Park, IL, ⁷AbbVie, Inc., North Chicago, IL, ⁸Abbvie, Winnetka, IL, ⁹Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland
Background/Purpose: To evaluate the long-term efficacy and safety of upadacitinib (UPA) over 5 yrs among patients with rheumatoid arthritis (RA) in a long-term extension (LTE)…
Abstract Number: 0511 • ACR Convergence 2022
SARS-CoV-2 mRNA Vaccine Immunogenicity in Chronic Inflammatory Arthritis on DMARD Therapy
Nedal Darwish¹, Sameer Jhaveri², Uma Yoganathan¹, Halima Bakillah¹, Kelly Y. Chun³, Thomas Wasser⁴ and James Freeman¹, ¹Arnot Ogden Medical Center, Elmira, NY, ²Lake Erie College of Osteopathic Medicine, Elmira, NY, ³Labcorp, Calabasas, CA, ⁴Consult-Stat, Macungie, PA
Background/Purpose: Patients with chronic inflammatory arthritis (CIA) are at increased risk for the development and mortality from COVID-19. Vaccinations are integral to the management of…
Abstract Number: 0790 • ACR Convergence 2022
Sustainability of Immunogenicity of BNT162b2 Vaccine in Patients with Autoimmune Rheumatic Disease, a Retrospective Comparative Study
Omar Alsaed, Masautso Chaponda, Eman Satti, Hadil Ashour, Muna Almaslamani and Samar Al emadi, Hamad Medical Corporation, Doha, Qatar
Background/Purpose: The sustainability of the immunogenicity of BNT162b2 anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in patients with autoimmune rheumatic diseases (ARDs) receiving immunomodulators…
Abstract Number: 0925 • ACR Convergence 2022
Impact of Initiating Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs on Pain Medication Use in Patients with Rheumatoid Arthritis
Mengdong He¹, Yvonne Lee², Yinzhu Jin³, Rishi Desai³, Seanna Vine³ and Seoyoung Kim³, ¹UCLA David Geffen School of Medicine, Los Angeles, CA, ²Northwestern University, Chicago, IL, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Chronic pain associated with rheumatoid arthritis (RA) leads to impaired patient function and quality of life. Prior studies suggest initiation of disease-modifying antirheumatic drugs…
Abstract Number: 1208 • ACR Convergence 2022
Development and Validation of a Prognostic Model for Methotrexate Discontinuation with Abnormal Monitoring Blood-test Results: A Cohort Study Using Data from Clinical Practice Research Datalink Gold and Aurum
Georgina Nakafero¹, Matthew J. Grainge¹, Tim Card¹, Maarten W Taal¹, Guruprasad P Aithal¹, Christopher P Fox², Christian Mallen³, Danielle van der Windt³, Richard Riley³ and Abhishek Abhishek¹, ¹University of Nottingham, Nottingham, United Kingdom, ²Nottingham University Hospital NHS Trust, Nottingham, United Kingdom, ³Keele University, Keele, United Kingdom
Background/Purpose: Patients established on long-term low-dose weekly methotrexate treatment undergo 3-monthly monitoring blood-tests to facilitate early detection of drug-related adverse events. Regular testing may not…
Abstract Number: 1493 • ACR Convergence 2022
Impact of Delay of Treatment with Disease Modifying Antirheumatic Drugs (DMARDs) in Psoriatic Arthritis: Lessons from the CorEvitas PsA/SpA Registry
Philip J Mease¹, Miroslawa Nowak², Jiyoon Choi³, Tom Lehman², Antoine Sreih⁴, Taylor Blachley⁵, Blessing Dube⁵, Kaylee Ho⁵, Nicole Middaugh⁵ and Alexis Ogdie⁶, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Bristol Myers Squibb, Princeton, NJ, ³Bristol Myers Squibb, Lawrenceville, NJ, ⁴Bristol Myers Squibb, Philadelphia, PA, ⁵CorEvitas, LLC, Waltham, MA, ⁶Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: There is evidence that a delay between psoriatic arthritis (PsA) symptom onset and diagnosis contributes to worse outcomes, yet the impact of delayed DMARD…
Abstract Number: 1954 • ACR Convergence 2022
Development of the Patient-Important Outcomes Data Repository (PIONEER) for Rheumatic Diseases; An Enhanced Database Combining Electronic Medical Data with Insight from Chart Reviews
Simon Helfgott¹, Kent Kwas Huston², Jasvinder singh³, Nehad Soloman⁴, Jeremy Broestl⁵, Kimmi Cox⁵, Kelsey Milligan⁵ and Colin Edgerton⁶, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Kansas City Physician Partners Center for Rheumatic Disease, Kansas City, MO, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ⁵Trio Health, Louisville, CO, ⁶Articularis Healthcare, Sullivans Island, SC
Background/Purpose: Clinical and non-clinical forces contribute to real-world treatment effectiveness, yet most studies focus on efficacy in an idealized setting. To identify factors impacting clinical…
Abstract Number: 2144 • ACR Convergence 2022
JAK Inhibition Re-balances Gene Expression Profile of Circulating Immune Cells in Patients with Psoriatic Arthritis
Maria Gabriella Raimondo¹, Charles Gwellem Anchang¹, Hannah Labinsky², Mina Saad Aziz Saad¹, Simon Rauber¹, Mario Vogg¹, Eleni Kampylafka¹, Johannes Knitza¹, Alina Soare¹, Georg Schett³ and Andreas Ramming¹, ¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Janus Kinase (JAK)/Signal Transducers and Activator of Transcription (STAT) is not only involved in IL23- signaling, but rather implemented into a broad range of…
Abstract Number: L01 • ACR Convergence 2021
Immunogenicity of mRNA COVID-19 Vaccines at 4 and 12 Weeks Post Full Vaccination in Patients with Inflammatory Rheumatic Diseases
Catherine Raptis¹, Diego Andrey², Christoph Berger³, Axel Finckh², Pierre Lescuyer², Adrian Ciurea⁴, Tanja Maletic¹, Christos Polysopoulos¹, Myriam Riek¹, Almut Scherer¹, Kim Lauper², Burkhard Moeller⁵, Judith Safford⁶, Sandra Schweizer⁷, Isabell von Loga¹, Nicolas Vuilleumier⁸ and Andrea Rubbert-Roth⁹, ¹SCQM Foundation, Zurich, Switzerland, ²Geneva University Hospital, Geneva, Switzerland, ³University Hospital Basel, Basel, Switzerland, ⁴University Hospital Zurich, Zrich, Switzerland, ⁵Inselspital - University Hospital Bern, Bern, Switzerland, ⁶RheumaCura Foundation, Zurich, Switzerland, ⁷Swiss League Against Rheumatism, Zurich, Switzerland, ⁸University Hospital of Geneva, Geneva, Switzerland, ⁹Kantonspital St Gallen, St.Gallen, Switzerland
Background/Purpose: Emerging evidence indicates that immunosuppressive therapies may result in reduced immunogenicity –and presumably reduced efficacy- following vaccination with mRNA COVID-19 vaccines but long-term data…
Abstract Number: L11 • ACR Convergence 2021
Cardiovascular Risk of Hydroxychloroquine in the Treatment of Rheumatoid Arthritis: A Retrospective Cohort Study
ELVIRA D'ANDREA¹, Rishi Desai², Mengdong He³, Robert Glynn⁴, Hemin Lee², Michael Weinblatt², Daniel Solomon⁵ and Seoyoung Kim², ¹Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³UCLA David Geffen School of Medicine, Los Angeles, CA, ⁴Brigham & Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Newton, MA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used 1st-line disease-modifying antirheumatic drug (DMARD) for patients with rheumatoid arthritis (RA) in the U.S., while methotrexate (MTX) is…
Abstract Number: L13 • ACR Convergence 2021
Efficacy and Safety of Subcutaneous Belimumab (BEL) and Rituximab (RTX) Sequential Therapy in Patients with Systemic Lupus Erythematosus: The Phase 3, Randomized, Placebo-Controlled BLISS-BELIEVE Study
Cynthia Aranow¹, Cornelia Allaart², Zahir Amoura³, Ian N Bruce⁴, Patricia Cagnoli⁵, Richard Furie¹, Paul Peter Tak⁶, Murray Urowitz⁷, Ronald van Vollenhoven⁸, Kenneth L Clark⁶, Mark Daniels⁹, Norma Lynn Fox¹⁰, Yun Irene Gregan¹⁰, James Groark¹¹, Robert B Henderson⁹, Mary Oldham⁹, Don Shanahan⁹, Andre van Maurik⁹, David A Roth¹⁰ and YK Onno Teng², ¹Feinstein Institutes for Medical Research, Northwell Health, Great Neck, NY, ²Leiden University Medical Center, Leiden, Netherlands, ³Centre National de reference pour le Lupus, Service de Medecine Interne 2, Institut E3M, Hopital Pitié-Salpétrière, Paris, France, ⁴NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Trust and Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁵University of Michigan Medical Center, Ann Arbor, MI, ⁶GlaxoSmithKline (At the time of the author's contribution to this study), Stevenage, United Kingdom, ⁷Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ⁸Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁹GlaxoSmithKline, Stevenage, United Kingdom, ¹⁰GlaxoSmithKline, Collegeville, PA, ¹¹GlaxoSmithKline (At the time of the author's contribution to this study), Collegeville, PA
Background/Purpose: Disease control remains an unmet need in SLE. The rationale for sequential BEL and RTX therapy in SLE was previously published.1 This study evaluated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].